Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types
Background: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this stud...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/1/42 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588718530101248 |
|---|---|
| author | Hironari Tamiya Kazumi Nishino Yuji Kato Reina Nakahashi-Kato Yurika Kosuga-Tsujimoto Shota Kinoshita Rie Suzuki Makiyo Watanabe Toru Wakamatsu Shigeki Kakunaga Satoshi Takenaka |
| author_facet | Hironari Tamiya Kazumi Nishino Yuji Kato Reina Nakahashi-Kato Yurika Kosuga-Tsujimoto Shota Kinoshita Rie Suzuki Makiyo Watanabe Toru Wakamatsu Shigeki Kakunaga Satoshi Takenaka |
| author_sort | Hironari Tamiya |
| collection | DOAJ |
| description | Background: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this study, we investigated whether BMA was involved in post-bone metastasis survival. Methods: A total of 539 cancer patients were retrospectively analyzed to identify significant independent factors in post-bone metastasis survival. Results: Among the overall population, patients with the following cancers had a median survival longer than 24 months: thyroid, 97.2 months; breast, 51.5 months; prostate, 47.2 months; and kidney, 38.8 months. In contrast, median post-bone metastasis survival was significantly shorter in gastrointestinal (GI) (6.5 months), head and neck (6.3 months), and urinary tract (3.4 months) cancers. In non-small cell lung cancer (NSCLC), the log-rank test demonstrated that the epidermal growth factor receptor (EGFR) mutation was a significant factor for post-bone metastasis survival: EGFR mutation (−) <i>n</i> = 67, median post-bone metastasis survival 11.5 months (95% CI: 6.0–15.2); EGFR mutation (+) <i>n</i> = 39, median post-bone metastasis survival 28.8 months (95% CI: 18.1–35.7) (<i>p</i> < 0.05). Intriguingly, treatment with BMA was a significant positive prognostic factor: BMA (−) <i>n</i> = 203, median post-bone metastasis survival 7.8 months (95% CI: 5.8–12.5); BMA (+) <i>n</i> = 336, median post-bone metastasis survival 21.9 months (95% CI: 16.1–26.4) (<i>p</i> < 0.001). Moreover, the Cox proportional hazards model showed that this was particularly evident in cancer types with poor prognosis such as GI cancer (hazard ratio [HR]: 0.62, 95% CI: 0.40–0.95; <i>p</i> < 0.05) and NSCLC without the epidermal growth factor receptor (EGFR) mutation (HR: 0.56, 95% CI: 0.34–0.91; <i>p</i> < 0.05). Conclusions: Treatment with BMA is recommended not only for the prevention and/or treatment of SRE, but also may have a positive impact on post-bone metastasis survival, particularly in cancers with typically poor post-bone metastasis survival such as GI cancer and NSCLC without the EGFR mutation. |
| format | Article |
| id | doaj-art-affe7433eb9540ada557f255c712bf0d |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-affe7433eb9540ada557f255c712bf0d2025-01-24T13:28:27ZengMDPI AGCurrent Oncology1198-00521718-77292025-01-013214210.3390/curroncol32010042Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer TypesHironari Tamiya0Kazumi Nishino1Yuji Kato2Reina Nakahashi-Kato3Yurika Kosuga-Tsujimoto4Shota Kinoshita5Rie Suzuki6Makiyo Watanabe7Toru Wakamatsu8Shigeki Kakunaga9Satoshi Takenaka10Department of Rehabilitation, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Rehabilitation, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Rehabilitation, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Rehabilitation, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Rehabilitation, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanBackground: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this study, we investigated whether BMA was involved in post-bone metastasis survival. Methods: A total of 539 cancer patients were retrospectively analyzed to identify significant independent factors in post-bone metastasis survival. Results: Among the overall population, patients with the following cancers had a median survival longer than 24 months: thyroid, 97.2 months; breast, 51.5 months; prostate, 47.2 months; and kidney, 38.8 months. In contrast, median post-bone metastasis survival was significantly shorter in gastrointestinal (GI) (6.5 months), head and neck (6.3 months), and urinary tract (3.4 months) cancers. In non-small cell lung cancer (NSCLC), the log-rank test demonstrated that the epidermal growth factor receptor (EGFR) mutation was a significant factor for post-bone metastasis survival: EGFR mutation (−) <i>n</i> = 67, median post-bone metastasis survival 11.5 months (95% CI: 6.0–15.2); EGFR mutation (+) <i>n</i> = 39, median post-bone metastasis survival 28.8 months (95% CI: 18.1–35.7) (<i>p</i> < 0.05). Intriguingly, treatment with BMA was a significant positive prognostic factor: BMA (−) <i>n</i> = 203, median post-bone metastasis survival 7.8 months (95% CI: 5.8–12.5); BMA (+) <i>n</i> = 336, median post-bone metastasis survival 21.9 months (95% CI: 16.1–26.4) (<i>p</i> < 0.001). Moreover, the Cox proportional hazards model showed that this was particularly evident in cancer types with poor prognosis such as GI cancer (hazard ratio [HR]: 0.62, 95% CI: 0.40–0.95; <i>p</i> < 0.05) and NSCLC without the epidermal growth factor receptor (EGFR) mutation (HR: 0.56, 95% CI: 0.34–0.91; <i>p</i> < 0.05). Conclusions: Treatment with BMA is recommended not only for the prevention and/or treatment of SRE, but also may have a positive impact on post-bone metastasis survival, particularly in cancers with typically poor post-bone metastasis survival such as GI cancer and NSCLC without the EGFR mutation.https://www.mdpi.com/1718-7729/32/1/42bone-modifying agentbone metastasissurvivalcancertreatment |
| spellingShingle | Hironari Tamiya Kazumi Nishino Yuji Kato Reina Nakahashi-Kato Yurika Kosuga-Tsujimoto Shota Kinoshita Rie Suzuki Makiyo Watanabe Toru Wakamatsu Shigeki Kakunaga Satoshi Takenaka Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types Current Oncology bone-modifying agent bone metastasis survival cancer treatment |
| title | Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types |
| title_full | Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types |
| title_fullStr | Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types |
| title_full_unstemmed | Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types |
| title_short | Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types |
| title_sort | impact of bone modifying agents on post bone metastasis survival across cancer types |
| topic | bone-modifying agent bone metastasis survival cancer treatment |
| url | https://www.mdpi.com/1718-7729/32/1/42 |
| work_keys_str_mv | AT hironaritamiya impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT kazuminishino impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT yujikato impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT reinanakahashikato impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT yurikakosugatsujimoto impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT shotakinoshita impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT riesuzuki impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT makiyowatanabe impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT toruwakamatsu impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT shigekikakunaga impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes AT satoshitakenaka impactofbonemodifyingagentsonpostbonemetastasissurvivalacrosscancertypes |